Peninsula biotech coughs up 40 percent of its value on failed clinical trial
October 08, 2018 at 17:43 PM EDT
The company raised $137 million in a January IPO, but its stock now is 64 percent lower than the IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.